Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Iovance Biotherapeutics, Inc.
Iovance Biotherapeutics Inc is a biopharmaceutical company in the United States. Its lead pipeline candidate, LN-144, uses the tumor-infiltrating lymphocytes to treat serious diseases.
IPO Date: October 23, 2013
Sector: Healthcare
Industry: Biotech
Market Cap: $980.51M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.46 | 3.17%
Avg Daily Range (30 D): $0.07 | 3.28%
Avg Daily Range (90 D): $0.10 | 4.08%
Institutional Daily Volume
Avg Daily Volume: 3.71M
Avg Daily Volume (30 D): 16.94M
Avg Daily Volume (90 D): 15.87M
Trade Size
Avg Trade Size (Sh.): 172
Avg Trade Size (Sh.) (30 D): 467
Avg Trade Size (Sh.) (90 D): 424
Institutional Trades
Total Inst.Trades: 5,325
Avg Inst. Trade: $2.54M
Avg Inst. Trade (30 D): $1.21M
Avg Inst. Trade (90 D): $1.31M
Avg Inst. Trade Volume: .23M
Avg Inst. Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $3.94M
Avg Closing Trade (30 D): $1.08M
Avg Closing Trade (90 D): $1.4M
Avg Closing Volume: 370.68K
   
News
Oct 17, 2025 @ 9:15 PM
Iovance Biotherapeutics Reports Inducement Grants ...
Source: Iovance Biotherapeutics, Inc.
Oct 17, 2025 @ 10:17 AM
Better Beaten-Down Stock: Iovance Biotherapeutics ...
Source: Prosper Junior Bakiny
Sep 17, 2025 @ 12:30 PM
Advancing Cancer Research Brings New Hope for Pati...
Source: Prnewswire
Aug 26, 2025 @ 5:00 PM
Untreated Metastatic or Unresectable Melanoma Clin...
Source: Delveinsight
Aug 24, 2025 @ 1:30 PM
1 Beaten-Down Stock That Could Soar By 261%, Accor...
Source: Prosper Junior Bakiny
Financials
  TTM Q2 2025 Q1 2025
Basic EPS $-.25 $-.33 $-.36
Diluted EPS $-.33 $-.36
Revenue $ 67.46M $ 59.95M $ 49.32M
Gross Profit $ 28.98M $ 3.29M $ -.42M
Net Income / Loss $ -91.25M $ -111.66M $ -116.16M
Operating Income / Loss $ -94.9M $ -113.77M $ -121.22M
Cost of Revenue $ 38.48M $ 56.66M $ 49.74M
Net Cash Flow $ 25.69M $ -39.64M $ 56M
PE Ratio    
Splits
Sep 26, 2013:   1:100
Apr 06, 2010:   24:1